These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Dapsone susceptibility of M. leprae before and after 1977. Almeida JG Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):726-7. PubMed ID: 3323374 [No Abstract] [Full Text] [Related]
44. Chemotherapy of leprosy. Shepard CC Annu Rev Pharmacol; 1969; 9():37-50. PubMed ID: 4892433 [No Abstract] [Full Text] [Related]
45. The mouse footpad test--sensitive to small proportions of drug-resistant bacilli in a sample of M. leprae. Almeida JG; Joseph PS; Sarangapani G; Chacko CJ Indian J Lepr; 1984; 56(1):10-4. PubMed ID: 6384379 [TBL] [Abstract][Full Text] [Related]
46. Application of spectrophotofluorometric procedures to some problems in Mycobacterium leprae infections in mice and man treated with dapsone (DDS), diacetyl-DDS (DADDS), and di-formyl-DDS (DFD). Ozawa T; Shepard CC; Karat AB Am J Trop Med Hyg; 1971 Mar; 20(2):274-81. PubMed ID: 4928595 [No Abstract] [Full Text] [Related]
47. The clinical diagnosis of dapsone resistant leprosy. Taylor PM Lepr India; 1982 Jan; 54(1):117-22. PubMed ID: 7047897 [TBL] [Abstract][Full Text] [Related]
48. The effect of rifampicin on Mycobacterium leprae in mice. Matsuo Y Jpn J Microbiol; 1974 Jan; 18(1):15-9. PubMed ID: 4605247 [No Abstract] [Full Text] [Related]
49. Combined clofazimine- and dapsone-resistant leprosy. A case report. Kar HK; Bhatia VN; Harikrishnan S Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):389-91. PubMed ID: 3528345 [TBL] [Abstract][Full Text] [Related]
50. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads. Dhople AM; Ortega I; Seydel JK; Gardner GD Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064 [TBL] [Abstract][Full Text] [Related]
51. [Sensitivity to dapsone, sulfamethoxypyridazine and ethionamide of mycobacterium leprae taken from patients treated by the drugs]. Pattyn SR; Rollier MT; Rollier R; Verdoolaeghe-Van Loo G Int J Lepr Other Mycobact Dis; 1975; 43(4):356-63. PubMed ID: 776843 [TBL] [Abstract][Full Text] [Related]
52. Potential antileprotic agents. 1. Inhibition of a model mycobacterial system by diaryl sulfones. Colwell WT; Chan G; Brown VH; DeGraw JI; Peters JH; Morrison NE J Med Chem; 1974 Jan; 17(1):142-4. PubMed ID: 4585972 [No Abstract] [Full Text] [Related]
53. Grades of dapsone resistance to Mycobacterium leprae (burrowing terminology). Roy RG Lepr India; 1983 Jan; 55(1):179-80. PubMed ID: 6348411 [No Abstract] [Full Text] [Related]
54. Studies on the determination of the minimal inhibitory concentration of 4,4'-diamino-diphenyl-sulphone (Dapsone, DDS) against Mycobacterium leprae. Ellard GA; Gammon PT; Rees RJ; Waters MF Lepr Rev; 1971 Jun; 42(2):101-17. PubMed ID: 4948480 [No Abstract] [Full Text] [Related]
55. An in vitro culture method for screening new drugs against Mycobacterium leprae. Dhople AM; Ortega I Indian J Lepr; 1990; 62(1):66-75. PubMed ID: 2193063 [TBL] [Abstract][Full Text] [Related]
56. Further experience with the kinetic method for the study of drugs against Mycobacterium leprae in mice. Activities of DDS, DFD, ethionamide, capreomycin and PAM 1392. Shepard CC Int J Lepr Other Mycobact Dis; 1969; 37(4):389-97. PubMed ID: 4918202 [No Abstract] [Full Text] [Related]
58. Primary dapsone resistance as assessed by uptake of labelled thymidine by the macrophage resident Mycobacterium leprae. Thakur M; Vaishnavi C; Ganguly NK; Kaur S; Kumar B Indian J Lepr; 1989 Oct; 61(4):437-41. PubMed ID: 2695575 [TBL] [Abstract][Full Text] [Related]
59. Primary and secondary dapsone resistance of M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras CC; Cartel JL; Constant-Desportes M; Millan J; Bobin P; Guidi C; Brucker G; Flageul B; Guillaume JC; Pichet C Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):672-9. PubMed ID: 3323369 [TBL] [Abstract][Full Text] [Related]